Skip to main content
Top
Published in: Tumor Biology 5/2014

01-05-2014 | Research Article

Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma

Authors: Shuang-Xiang Tan, Rui-Cheng Hu, Yong-Li Tan, Jing-Jing Liu, Wen-En Liu

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

PRDM5 has been proposed as a tumor suppressor frequently downregualted in tumor. In this study, lung squamous cell carcinoma tissues and adjacent nontumorous normal tissues were collected from 30 patients. PRDM5 expression was detected by reverse transcription polymerase chain reaction and Western blot analysis, DNA methylation of PRDM5 promoter was analyzed by methylation-specific PCR. SK-MES-1 cells or xenografts in nude mice were treated with 5-aza-2′-deoxycitydine, and cell proliferation and tumor growth in nude mice were examined. We found that PRDM5 promoter was methylated and PRDM5 expression at both mRNA and protein levels was reduced in lung squamous cell carcinoma tissues. Furthermore, PRDM5 promoter methylation was significantly correlated with tumor differentiation and lymph node metastasis of lung squamous cell carcinoma, but not with age, gender, smoking, or tumor grade. 5-aza-2′-deoxycitydine inhibited the proliferation of SK-MES-1 cells and the growth of xenografts in nude mice, accompanied by reduced methylation of PRDM5 promoter and increased expression of PRDM5. Taken together, our data suggest that PRDM5 is a tumor suppressor in lung cancer and is a promising target for the diagnosis, prognosis, and therapy of lung squamous cell carcinoma.
Literature
1.
2.
go back to reference Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012;13:e418–26.CrossRefPubMed Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012;13:e418–26.CrossRefPubMed
3.
go back to reference Brzeziańska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis. Mol Biol Rep. 2013;40:309–25.CrossRefPubMed Brzeziańska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis. Mol Biol Rep. 2013;40:309–25.CrossRefPubMed
4.
go back to reference Zhang Y, Xu R, Li G, Xie X, Long J, Wang H. Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells. Tumour Biol. 2012;33:1915–25.CrossRefPubMed Zhang Y, Xu R, Li G, Xie X, Long J, Wang H. Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells. Tumour Biol. 2012;33:1915–25.CrossRefPubMed
5.
go back to reference Yu Y, Yin D, Hoque MO, Cao B, Jia Y, Yang Y, et al. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. Tumour Biol. 2012;33:307–14.CrossRefPubMed Yu Y, Yin D, Hoque MO, Cao B, Jia Y, Yang Y, et al. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. Tumour Biol. 2012;33:307–14.CrossRefPubMed
7.
go back to reference Fog CK, Galli GG, Lund AH. PRDM proteins: important players in differentiation and disease. Bioessays. 2012;34:50–60.CrossRefPubMed Fog CK, Galli GG, Lund AH. PRDM proteins: important players in differentiation and disease. Bioessays. 2012;34:50–60.CrossRefPubMed
8.
go back to reference Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene. 2004;23:4903–10.CrossRefPubMed Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene. 2004;23:4903–10.CrossRefPubMed
9.
go back to reference Cheng HY, Chen XW, Cheng L, et al. DNA methylation and carcinogenesis of PRDM5 in cervical cancer. J Cancer Res Clin Oncol. 2010;136:1821–5.CrossRefPubMed Cheng HY, Chen XW, Cheng L, et al. DNA methylation and carcinogenesis of PRDM5 in cervical cancer. J Cancer Res Clin Oncol. 2010;136:1821–5.CrossRefPubMed
10.
go back to reference Watanabe Y, Toyota M, Kondo Y, et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res. 2007;13:4786–94.CrossRefPubMed Watanabe Y, Toyota M, Kondo Y, et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res. 2007;13:4786–94.CrossRefPubMed
11.
12.
go back to reference Khandige S, Shanbhogue VV, Chakrabarty S, Kapettu S. Methylation markers: a potential force driving cancer diagnostics forward. Oncol Res. 2011;19:105–10.CrossRefPubMed Khandige S, Shanbhogue VV, Chakrabarty S, Kapettu S. Methylation markers: a potential force driving cancer diagnostics forward. Oncol Res. 2011;19:105–10.CrossRefPubMed
13.
go back to reference Van Den Broeck A, Ozenne P, Eymin B, et al. Lung cancer: a modified epigenome. Cell Adh Migr. 2010;4:107–13.CrossRef Van Den Broeck A, Ozenne P, Eymin B, et al. Lung cancer: a modified epigenome. Cell Adh Migr. 2010;4:107–13.CrossRef
14.
go back to reference Ding HL, Clouthier DE, Artinger KB. Redundant roles of PRDM family members in zebrafish craniofacial development. Dev Dyn. 2013;242:67–79.CrossRefPubMed Ding HL, Clouthier DE, Artinger KB. Redundant roles of PRDM family members in zebrafish craniofacial development. Dev Dyn. 2013;242:67–79.CrossRefPubMed
15.
go back to reference Hohenauer T, Moore AW. The Prdm family: expanding roles in stem cells and development. Development. 2012;139:2267–82.CrossRefPubMed Hohenauer T, Moore AW. The Prdm family: expanding roles in stem cells and development. Development. 2012;139:2267–82.CrossRefPubMed
16.
go back to reference Kinameri E, Inoue T, Aruga J, et al. Prdm proto-oncogene transcription factor family expression and interaction with the Notch-Hes pathway in mouse neurogenesis. PLoS One. 2008;3:e3859.CrossRefPubMedPubMedCentral Kinameri E, Inoue T, Aruga J, et al. Prdm proto-oncogene transcription factor family expression and interaction with the Notch-Hes pathway in mouse neurogenesis. PLoS One. 2008;3:e3859.CrossRefPubMedPubMedCentral
Metadata
Title
Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma
Authors
Shuang-Xiang Tan
Rui-Cheng Hu
Yong-Li Tan
Jing-Jing Liu
Wen-En Liu
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1593-2

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine